Psoriatic Arthritis Treatment Market
Report ID: SQMIG35I2688
Report ID: SQMIG35I2688
[email protected]
USA +1 351-333-4748
Report ID:
SQMIG35I2688 |
Region:
Global |
Published Date: May, 2026
Pages:
157
|Tables:
144
|Figures:
78
Global Psoriatic Arthritis Treatment Market size was valued at USD 12.52 Billion in 2024 and is poised to grow from USD 13.39 Billion in 2025 to USD 22.85 Billion by 2033, growing at a CAGR of 6.92% during the forecast period (2026-2033).
The market for psoriatic arthritis treatment market growth is mainly driven by increased awareness of the disease and new therapies, which have changed how the disease is treated over the last 20 years. This market includes the following categories biologics prescribed as injections or infusions; Copay assistance offered through private or public health insurance coverage; Expansion of access to medications via generic products (compared with prescription drugs); Non-drug therapy (e.g., occupational therapy, physical therapy, etc.) to help manage symptoms; Homeopathic remedies and natural supplements for symptom relief; Financial support provided to patients unable to afford their medication; and Supportive care provided to patients who are disabled due to untreated progress of disease.
The use of Traditional Disease Modifying Anti-Rheumatic Drugs (DMARDs) was the most common form of treatment for psoriatic arthritis treatment market trends before TNF-alpha inhibitors and IL-17 or IL-23 targeted biopharmaceutical products became available. The introduction of these drugs gave people with psoriatic arthritis access to new treatment options and helped improve the global uptake of treatment. The primary factors affecting growth are improvements in diagnostic algorithms and changes in reimbursement practices. Improving early diagnoses through better patient evaluations will initiate targeted therapies sooner, and most payers now provide reimbursement for high-cost, high-quality biopharmaceuticals administered to eligible patients. For instance, ultrasound used in musculoskeletal imaging has increased the detection of synovitis in rheumatology clinics, leading to increased use of IL-17 inhibitors to prevent erosion of the joint and to decrease long-term need for joint replacement surgery, with identified cost offsets. Additionally, small oral molecules (i.e., JAK inhibitors) have expanded treatment options for patients receiving outpatient care, improving compliance and making it easier for patients to switch from infusion therapy to oral therapy. These trends have created an environment in which manufacturers can invest in generating real-world evidence and launching patient support initiatives.
How is AI Improving Patient Stratification in the Psoriatic Arthritis Treatment Market?
AI enhances the process of classifying patients with psoriatic arthritis through the integration of eHealth records, imaging, genomics and patient reported outcomes to describe clinically relevant phenotypes and estimate responsiveness to therapy. Examples of current uses are screening algorithms, natural language processing of clinical notes, clustering of multiple disease manifestations and developing explainable models to predict flares and characteristics of potential responders. In a maturing market for rapid emergence of both treatments and varied needs of patients, these tools facilitate options for treatment selection and expedite enrollment into clinical trials. For instance, patient clusters have been identified in secukinumab, and real-world, multimodal models supports the earliest possible diagnosis and personalized treatment planning.
Bristol Myers Squibb recently announced (as of March 2026) FDA approval of Sotyktu for the treatment of psoriatic arthritis. AI-based classification systems assist clinicians in matching patients to an appropriate mechanism of action, streamlining decisions regarding prescription and accelerating post-marketing clinical trial enrolments and real world access.
Market snapshot - (2026-2033)
Global Market Size
USD 12.52 Billion
Largest Segment
TNF Inhibitors
Fastest Growth
IL-17 Inhibitors
Growth Rate
6.92% CAGR
To get more insights on this market click here to Request a Free Sample Report
Global psoriatic arthritis treatment market is segmented by drug class, route, line of therapy, distribution and region. Based on drug class, the market is segmented into TNF inhibitors, IL-17 inhibitors, IL-12/23 inhibitors, JAK inhibitors and PDE4 inhibitors. Based on route, the market is segmented into injectable and oral. Based on line of therapy, the market is segmented into first-line and second-line. Based on distribution, the market is segmented into hospital pharmacies, specialty pharmacies and online. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Strong evidence for sustained symptomatic control has made clinicians favor this class of medications for patients with both dermatologic and rheumatologic symptoms, and payer recognition and guideline inclusion facilitate the adoption of IL 17 inhibitors as documented evidence for long-term therapeutic reliability, allowing for formulary placement and long-term treatment plans, thus impacting market leadership. Strong evidence for sustained symptomatic control has made clinicians favor this class of medications for patients with both dermatologic and rheumatologic symptoms, and payer recognition and guideline inclusion facilitate the adoption of IL 17 inhibitors as documented evidence for long-term therapeutic reliability, allowing for formulary placement and long-term treatment plans, thus impacting market leadership.
However, JAK inhibitors are emerging as the fastest growing class due to oral administration, rapid symptomatic relief, and expanding label extensions that broaden eligible patient populations. Clinical innovation in selectivity and real world uptake among clinicians seeking flexibility are driving adoption, creating new therapeutic options that accelerate market expansion and value creation.
The injectable segment leads because previously established biologic therapies have a long-term history of controlling joint inflammation and limiting the development of structural progression in joints. As a result, the administration location of biologics, along with the specialty distribution network, allows for reliable dosing and monitoring of injectable products. To the extent that clinicians regularly prescribe injectable products for patients with moderate-to-severe disease, along with strong familiarity by payers and clinical managers for how they will be used in clinical practice, injectable products maintain a large degree of utilization within care pathways.
However, oral therapies are experiencing the strongest uptake driven by patient preference for pill based regimens, the advent of targeted small molecule agents, and simpler administration that supports adherence and outpatient management. Growing clinician confidence and expanding approvals for oral options are unlocking new treatment settings and creating pathways for earlier intervention and broader market opportunity.
To get detailed segments analysis, Request a Free Sample Report
North America has an established healthcare system with high quality of clinical services available, which is essential to lead in the area of psoriatic arthritis treatment. The payer systems available for reimbursing advanced therapies, a high level of awareness among healthcare providers and active representation by patients increase the speed at which new therapies are used by patients. The availability of many clinical research centres and early access programmes allows for faster introduction of new treatments into practice. The presence of large markets allows for aggressive investments in marketing and in the generation of real world evidence that supports clinician confidence. The presence of diagnostics and multiple specialties allows for timely identification and treatment of complex patients. Together, these factors create a competitive environment with a high level of ongoing innovation that drives North America’s leadership in the global market for psoriatic arthritis.
Psoriatic arthritis treatment market share in the United States is characterized by rapid adoption of innovative biologic and targeted therapies, a dense network of specialist clinics, and extensive clinical trial activity. Strong commercialization capabilities among manufacturers support overall product availability. Reimbursement frameworks generally facilitate access to advanced treatment options, while competition among leading companies drives continued investment in real world evidence, patient support programs, and physician education to optimize disease management.
Psoriatic arthritis treatment market forecast in Canada is characterized by a strong focus on equitable access via public healthcare systems, while reimbursement and formulary placement are determined by provincial decisions for where the agents will have best utilization. Urban centers serve as specialist care providers for psoriatic arthritis patients who have access to the most up-to-date therapy options, made possible through collaborative networks that connect physician and researcher stakeholders. New treatment options are introduced based on evidence and negotiated pathways, with the contribution of patient organizations to enhance public awareness and support patient adherence as key components in patient treatment selection and health system priorities related to psoriatic arthritis.
Expansion in Europe is driven by a combination of strengthening clinical networks, active health technology assessment frameworks, and strategic commercialization by global and regional pharmaceutical companies. Centralized and national reimbursement pathways encourage systematic evaluation of novel therapies alongside growing adoption of biosimilar options that broaden access. Increasing collaboration among rheumatology centers, registry development, and cross border research initiatives enhance diagnosis and evidence generation. Patient advocacy and guideline harmonization promote standardized care pathways, while payer emphasis on cost effectiveness compels manufacturers to demonstrate value through outcomes data and supportive services. Variation across markets creates differentiated entry strategies, prompting tailored pricing and access arrangements that collectively accelerate treatment availability and clinical adoption throughout the region. Investment in real world evidence platforms and digital health initiatives supports patient monitoring and outcomes-based contracting, while targeted awareness campaigns increase diagnosis rates and specialist referrals, reinforcing market momentum across diverse European healthcare systems.
Psoriatic arthritis treatment market regional outlook in Germany demonstrates a strong connection between research and advancement of new therapies through efficient development systems that allow for the rapid availability of these products to patients after treatment begins; In addition, the infrastructure within Germany (for example, a highly developed health system and an extensive network of specialists) allows for effective translation of published clinical results into daily use; Manufacturers focus primarily on conducting locally based clinical trials and documenting their results; Furthermore, in Europe particularly, specific reimbursement policies and clinical pathways influenced by expert review boards help to define how physicians will adopt new therapies.
Psoriatic arthritis treatment market regional forecast in the United Kingdom is characterized by dynamic uptake propelled by national policy mechanisms and assessment streamlining access for clinicians and patients. Registry analytics and real world data inform commissioning decisions, while targeted adoption programs and clinician networks accelerate diffusion of newer therapies. Patient advocacy, integrated care pathways, and investment in specialist services contribute to rapid expansion, although regional commissioning variations require tailored market access strategies.
Psoriatic arthritis treatment market analysis in France is experiencing development and opportunity attributable to changing reimbursement models, as well as increased collaboration between manufacturers and health authorities. Improved clinical networks and centres of excellence promote additional specialist referrals and acceptance of new treatment modalities. Additionally, a greater focus on health technology assessments (HTA) and negotiated pricing mechanisms will facilitate market entry when the value of the new product(s) is demonstrated. Furthermore, patient advocacy and physician societies will continue to impact the development of clinical guidelines, thereby creating further opportunities for the growth of the psoriatic arthritis treatment market.
Asia Pacific is strengthening its position through expanded clinical capacity, regulatory modernization, and growing collaboration between local manufacturers and multinational companies. Investments in specialized healthcare facilities and targeted clinician education increase adoption of advanced therapies in urban centers, while national insurance reforms and evolving reimbursement approaches enhance affordability and access. Regional participation in multinational clinical trials and development of local evidence platforms support market entry and adaptation of treatment strategies to local patient profiles. Proliferation of domestic biotech innovation and cost-competitive manufacturing improves supply resilience, and digital health solutions facilitate remote monitoring and specialist consultation, collectively elevating the role of Asia Pacific in the global psoriatic arthritis treatment landscape. Growing patient awareness campaigns, expansion of local guideline development, and strategic public private partnerships further support scalable access, while outcome based contracting trials and targeted pricing strategies enable sustainable adoption across diverse markets.
Psoriatic arthritis treatment industry in Japan continues to thrive due to its well-established healthcare system as well as its numerous specialist networks and established pathways for the development of new therapies through regulation; however, both strong domestic development capabilities and the active participation of Japan's pharmaceutical companies in international clinical trials support the generation of evidence. Reimbursement eligibility, based on defined criteria within the insurance framework, allows for improved patient access. Additionally, the expertise of clinicians, combined with the large number of centers of excellence within the country's healthcare system, encourages the receipt of proper diagnosis, continued care and use of treatment innovations specifically adapted to local practice.
Psoriatic arthritis treatment market in South Korea is supported by an advanced healthcare system and vibrant domestic biotech sector that expedites development and adoption of novel therapies. Strong hospital networks and centralized procurement mechanisms enable efficient distribution, while evolving reimbursement processes and outcome based programs improve access. Active participation in multinational trials and collaborative industry government initiatives further strengthen clinical capabilities and facilitate tailored market strategies for broader regional reach.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Advancements In Biologic Therapies
Rising Patient Awareness Levels
High Cost Of Therapies
Limited Long Term Evidence
Request Free Customization of this report to help us to meet your business objectives.
As the biopharma landscape continues to diversify based on distinct MOAs and thus create both new licensing opportunities and partnership/acquisition opportunities, the global competitive landscape of psoriatic arthritis treatments will continue to increase. A few examples include the licensing of sonelokimab from Merck KGaA to MoonLake, Acelyrin moving the izokibep Affibody into late stage studies and completing strategic acquisitions, and Sudo Biosciences raising a Series A in order to support the development of their TYK2 program.
Top Player’s Company Profile
Recent Developments in the Psoriatic Arthritis Treatment Market
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research. As per SkyQuest analysis, the global psoriatic arthritis treatment market is advancing, a key driver is rising disease recognition and rapid therapeutic innovation that expands targeted biologics and small molecules and reshapes care pathways. A restraint is the high cost of therapies, which limits access and prompts restrictive payer policies. The dominating region is North America, supported by advanced healthcare infrastructure, strong clinical networks and favorable reimbursement, while the dominating segment remains injectable biologics due to proven efficacy and specialty distribution. A second driver is the growing adoption of oral small molecules and digital care integration, which improve adherence, broaden outpatient management and create opportunities for real-world evidence and patient support programs.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 12.52 Billion |
| Market size value in 2033 | USD 22.85 Billion |
| Growth Rate | 6.92% |
| Base year | 2024 |
| Forecast period | (2026-2033) |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Psoriatic Arthritis Treatment Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Psoriatic Arthritis Treatment Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Psoriatic Arthritis Treatment Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Psoriatic Arthritis Treatment Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Global Psoriatic Arthritis Treatment Market size was valued at USD 12.52 Billion in 2024 and is poised to grow from USD 13.39 Billion in 2025 to USD 22.85 Billion by 2033, growing at a CAGR of 6.92% during the forecast period (2026-2033).
The competitive landscape in the global psoriatic arthritis treatment market is intensifying as biopharma and clinical-stage startups pursue differentiated mechanisms, driving licensing, partnerships, and acquisitions. Examples include MoonLake licensing sonelokimab from Merck KGaA , Acelyrin advancing the izokibep Affibody into late stage studies and completing strategic acquisitions , and TYK2-focused Sudo Biosciences securing series A backing. 'AbbVie Inc. (Humira, Rinvoq)', 'Johnson & Johnson (Tremfya, Simponi)', 'Pfizer Inc. (Enbrel, Xeljanz)', 'Novartis AG (Cosentyx, Taltz co-marketed)', 'Eli Lilly (Taltz)', 'UCB SA (Cimzia)', 'Bristol Myers Squibb (Orencia)', 'Amgen Inc. (Enbrel co-marketed)', 'Biogen (Otezla partnership)', 'Celgene/BMS (Otezla)', 'Sun Pharmaceutical', 'Merck & Co.', 'AstraZeneca', 'Boehringer Ingelheim', 'Galapagos NV', 'Gilead Sciences (Filgotinib)', 'Moonlake Immunotherapeutics', 'Acelyrin Inc.', 'Sonoma Biotherapeutics', 'Affibody AB'
Advancements in biologic therapies have expanded therapeutic options and improved clinical outcomes for patients with psoriatic arthritis, encouraging clinicians to recommend targeted treatments more confidently. Enhanced efficacy and tailored mechanisms of action have driven wider adoption among specialist prescribers, supported ongoing research and pipeline activity, and fostered collaboration between biotechnology firms and healthcare providers. These developments have strengthened treatment guidelines and increased perceived value of innovative products, thereby stimulating investment, market entry of new agents, and broader availability of advanced therapies across care settings.
Precision Medicine Adoption: Growing emphasis on molecularly targeted pathways is driving therapeutic approaches in psoriatic arthritis management. Clinicians and biotech developers prioritize biomarker-driven patient stratification to match mechanisms of disease with specific agents, improving therapeutic alignment and tolerability. This trend fosters collaboration between diagnostics and pharmaceutical stakeholders, encourages adaptive clinical trial designs, and supports reimbursement narratives focused on value. Health systems increasingly seek tailored regimens that reduce trial-and-error prescribing while enhancing patient adherence and outcomes through more predictable responses and fewer adverse effects.
Why does North America Dominate the Global Psoriatic Arthritis Treatment Market? |@12
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
